Osteoporosis International

, 22:2597

Relationship between serum RANKL and RANKL in bone


DOI: 10.1007/s00198-011-1740-9

Cite this article as:
Findlay, D.M. & Atkins, G.J. Osteoporos Int (2011) 22: 2597. doi:10.1007/s00198-011-1740-9


It is now well accepted that the molecule receptor activator of NFκB ligand (RANKL) and osteoprotegerin play key roles in regulating physiological and pathological bone turnover. There are a large number of published reports of circulating RANKL levels in both health and pathology. However, interpretation of these data has been elusive, and the relationship between circulating RANKL and RANKL levels in bone is still not clear. This review explores this subject, documenting the possible origins of circulating RANKL and suggesting additional information that is required before serum RANKL levels can provide useful diagnostic or research information.


BonemRNARANK ligandSerum

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2011

Authors and Affiliations

  1. 1.Discipline of Orthopaedics and TraumaUniversity of AdelaideAdelaideAustralia
  2. 2.Hanson InstituteAdelaideAustralia